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OBJECTIVE — The expression of vascular endothelial growth factor (VEGF) is elevated
in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We
investigated the safety and efﬁcacy of ranibizumab in DME involving the foveal center.
RESEARCH DESIGN AND METHODS — This was a 12-month, multicenter, sham-
controlled, double-masked study with eyes (age 18 years, type 1 or 2 diabetes, central
retinalthickness[CRT]300m,andbestcorrectedvisualacuity[BCVA]of73–39ETDRS
letters [Early Treatment Diabetic Retinopathy Study]) randomly assigned to intravitreal
ranibizumab (0.3 or 0.5 mg; n  51 each) or sham (n  49). The treatment schedule
comprisedthreemonthlyinjections,afterwhichtreatmentcouldbestopped/reinitiatedwith
an opportunity for rescue laser photocoagulation (protocol-deﬁned criteria). After month 1,
dose-doubling was permitted (protocol-deﬁned criteria, injection volume increased from
0.05 to 0.1 ml and remained at 0.1 ml thereafter). Efﬁcacy (BCVA and CRT) and safety were
compared between pooled ranibizumab and sham arms using the full analysis set (n  151,
patients receiving 1 injection).
RESULTS — At month 12, mean  SD BCVA improved from baseline by 10.3  9.1 letters
with ranibizumab and declined by 1.4  14.2 letters with sham (P  0.0001). Mean CRT
reductionwas194.2135.1mwithranibizumaband48.4153.4mwithsham(P0.0001).
Gain of 10 letters BCVA from baseline occurred in 60.8% of ranibizumab and 18.4% of sham eyes
(P  0.0001). Safety data were consistent with previous studies of intravitreal ranibizumab.
CONCLUSIONS — Ranibizumab is effective in improving BCVA and is well tolerated in
DME. Future clinical trials are required to conﬁrm its long-term efﬁcacy and safety.
Diabetes Care 33:2399–2405, 2010
D
iabetes affects 220 million people
worldwide (1). Diabetic macular
edema (DME) is one of the major
causes of visual impairment (VI) in pa-
tients with diabetic retinopathy (2,3).
With diabetes prevalence estimated to
doubleduringthenext20years(4),inthe
futureitislikelythatDMEmayberespon-
sible for substantial vision loss unless
treated adequately.
Laser photocoagulation is the main-
stay of DME treatment; it reduces the risk
of moderate vision loss by 50%, with
3% of eyes showing vision improvement
(3lines),butasubstantialproportionof
treatedeyesremainunresponsive(5).Ina
recent report of a 2-year study, focal/grid
laserphotocoagulationwasmoreeffective
andhadfewersideeffectsthanintravitreal
triamcinolone acetonide (6). Pars plana
vitrectomy is another treatment modality
investigated for DME; however, both in-
travitreal triamcinolone acetonide and
pars plana vitrectomy have limited efﬁ-
cacy and/or signiﬁcant side effects (7,8).
There is currently a signiﬁcant unmet
medical need for an effective DME treat-
mentthatnotonlystabilizesbutimproves
and maintains vision and has a better
safety proﬁle than the available DME
treatment options. Several proinﬂamma-
tory cytokines including vascular endo-
thelial growth factor (VEGF) have been
shown to be extensively involved in the
development and progression of DME
(9). VEGF promotes neovascularization
andmicrovascularleakage(10).Thus,in-
hibitingVEGFmayprovideanalternative
therapeutic approach in DME. Anti-
VEGFagentshavebeenextensivelyinves-
tigated in neovascular age-related
macular degeneration (nAMD). Given
thatanti-VEGFdrugsdeliveredwithinthe
vitreous could pass into the systemic cir-
culation, VEGF inhibition could in turn
produce systemic adverse effects, which
maybepotentiallyseriousfordiabeticpa-
tients (11). Therefore, randomized clini-
caltrialsarerequiredtoestablishboththe
efﬁcacy and systemic adverse effects in
this population.
Ranibizumab is a fully humanized
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which binds to multiple variants of
VEGF-A (12), and is approved for the
treatment of nAMD. In a pilot study (10
patients with DME), ranibizumab was ef-
fective and well tolerated in maintaining
or improving best-corrected visual acuity
(BCVA) and in reducing central retinal
thickness (CRT) (13). The 6-month
Ranibizumab for Edema of the Macula in
Diabetes (READ-2) study (phase II) was
the ﬁrst to compare the efﬁcacy of ranibi-
zumab with laser photocoagulation or a
combination of both in patients with VI
due to DME; ranibizumab led to signiﬁ-
cant improvements in mean BCVA (7.2
letters) compared with laser photocoagu-
lation (0.4 letters) or the combination
(3.8 letters) (14). Studies in DME have
also been conducted with other anti-
VEGF agents, pegaptanib and bevaci-
zumab (15–19). Initial results from these
studies are encouraging in some patients
with DME; further prospective random-
ized clinical trials may conﬁrm their ef-
fects in DME.
We report the results of the phase II
RESOLVEstudyinpatientswithVIdueto
DME. This study evaluated the efﬁcacy
and safety of ranibizumab compared with
sham treatment over 12 months.
RESEARCH DESIGN AND
METHODS
Inclusion and exclusion criteria
Patients(aged18years)withtype1or2
diabetes and DME were eligible if they
had a visual acuity between 20/40 and
20/160, CRT 300 m, HbA1C 12%,
decreased vision attributed to foveal
thickening from DME, that was not ex-
plained by any other cause, and clinically
signiﬁcant DME in at least one eye con-
ﬁrmed by a central reading center (Bern
Photographic Reading Centre, University
Bern, Bern, Switzerland) using stereo-
scopic fundus photographs, ﬂuorescein
angiography, and optical coherence to-
mography (OCT) (Stratus OCT; Carl
Zeiss Meditec, Jena, Germany). Eyes were
deemed eligible if, in the judgment of the
investigator, laser photocoagulation
could be safely withheld in the study eye
for at least 3 months after random assign-
ment. Patients were excluded if they had
unstable medical status including glyce-
mic control and blood pressure or pan-
retinal laser photocoagulation performed
within 6 months before study entry, and
grid/central laser photocoagulation was
excluded except for patients with only
mild laser burns at least 1,000 m from
the center of the fovea performed 6
months preceding day 1. Details are
found in supplementary Table 1 (avail-
able in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc10-0493/DC1).
Study design
Of the 207 screened patients, 151 eligible
patients were randomly assigned 1:1:1 to
eitherranibizumab(0.3mg,n51or0.5
mg, n  51) or sham treatment (n  49)
(randomization details are found in the
supplementary data, available in an on-
line appendix). Before each scheduled
treatment, patients were asked to self-
administeratopicalantibacterialagentfor
3 days. Patients received three monthly
ranibizumab (0.3 or 0.5 mg) or sham in-
jections (injection volume 0.05 ml).
Thereafter,treatmentcouldbestoppedor
reinitiated based on treatment success,
disease activity, futility, or safety criteria
(supplementary Fig. 1, available in an on-
lineappendix).Itisimportanttonotethat
the sham arm was a nontreatment arm,
and patients did not receive intraocular
injections. The sham eyes were locally
anesthetized, and pressure with the blunt
tip of the syringe (without needle) was
applied to the anesthetized surface of the
eyetomimictheinjection.Aftermonth1,
the ranibizumab dose (or sham) could be
doubled by increasing the injection vol-
ume from 0.05 to 0.1 ml if CRT remained
300 m or was 225 m and the re-
duction in retinal edema from the previ-
ous assessment was 50 m. Once the
injection volume was increased to 0.1 ml,
subsequent administrations remained at
0.1 ml (0.6 or 1.0 mg ranibizumab). If
treatment had been withheld for 45
days,subsequentinjectionsrestartedwith
the initial injection volume of 0.05 ml.
Because of this possibility of dose dou-
bling, the ranibizumab treatment groups
are referred to as “0.3–0.6 mg” and “0.5–
1.0 mg.”
Thestudyincludedaplannedinterim
analysis at month 6 to facilitate early de-
cisions on dose, treatment ratio, sample
adjustments, or futility assessments (de-
tails are available in the supplementary
data).Here,wepresenttheoverallpooled
efﬁcacy and safety of ranibizumab
(pooled 0.3–0.6 mg with 0.5–1.0 mg)
versus sham treatment (by-dose data are
found in the supplementary data). The
primary end point was the mean average
changeinBCVAfrombaselinetomonth1
throughmonth12(chosenastheprimary
end point because it is less sensitive to
monthly variations and reﬂects the treat-
mentimpactovertheentiretreatmentpe-
riod). Secondary end points included
mean change in BCVA and CRT from
baseline to month 12, categorized BCVA
outcome, and safety.
The study was conducted in accor-
dance with the Declaration of Helsinki
and its subsequent amendments, Good
Clinical Practice, and applicable regula-
tory requirements. The research protocol
and its amendments were approved by
relevant institutional review boards and
ethics committees from the respective
study centers, and all participants gave
written informed consent.
Assessments
BCVA and CRT were assessed by certiﬁed
examinersusingEarlyTreatmentDiabetic
RetinopathyStudy(ETDRS)standardized
protocols and OCT, respectively, at
scheduled visits. Safety (ocular, nonocu-
lar,orsystemic)andvitalsigns(including
blood pressure [sitting systolic and dia-
stolic]) and serum levels of HbA1C were
assessed at each scheduled monthly visit.
The occurrence of adverse events (AEs)
was sought by nondirective questioning
of the patient at each visit, and these were
also recorded when reported by the pa-
tient during or between visits or through
physical examination, laboratory test, or
other assessments. Serious adverse events
(SAEs) were monitored continuously.
Routine hematology and systemic immu-
noreactivity assessments (i.e., presence of
serum antibodies against ranibizumab)
were performed at baseline and month 12.
Statistical analysis
The plan was to screen 225 patients to
achieve a sample size of 150 eligible pa-
tients within an estimated 12-month re-
cruitment period. The full analysis set
(FAS) was the primary efﬁcacy analysis
set. FAS comprised all patients who re-
ceived the study treatment at least once
(ranibizumab or sham) and who had at
least one post baseline BCVA assessment.
The safety population was identical to
the FAS.
For the primary efﬁcacy analysis,
missing data were imputed using the last
observation carried forward (LOCF)
method, with alternative missing data
handling procedures used for corre-
sponding sensitivity analysis. For statisti-
calhypothesistestingofthemeanaverage
changes from baseline in BCVA the strat-
iﬁed Cochran-Mantel-Haenszel test was
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tests) as scores (details of the hypothesis
testing are available in the supplementary
data). StatXact software was used to com-
pute the test.
In addition, the primary efﬁcacy vari-
able was assessed using parametric statis-
tical methods. The two-sided 95% CI for
the primary efﬁcacy variable and the cor-
responding difference in means between
treatments were calculated using the least
squares means from an ANOVA model
with treatment and categories of baseline
visual acuity and baseline CRT as factors.
RESULTS
Characteristics of patients
Patients from the ranibizumab and sham
arms were comparable with respect to
baseline characteristics (supplementary
Table 2, available in an online appendix).
Less than 20% of patients in all arms had
previously received laser photocoagula-
tion for DME. There were more discon-
tinuations in the sham arm than the
ranibizumabarm(18.4and9.8%,respec-
tively) (supplementary Fig. 2, available in
an online appendix).
Treatment characteristics:
adjustments and number of
treatments
The number of patients whose treatment
wasinterruptedorstoppedwascompara-
ble between the treatment arms (37
[36.3%]and20[40.8%],forranibizumab
and sham, respectively). Most treatment
adjustments in the sham arm were made
because of a lack of efﬁcacy (17 of 20
[85%] and 9 of 37 [24.3%] for sham and
ranibizumab, respectively); conversely,
for ranibizumab, they were prompted by
improved BCVA and/or reduced CRT (17
of 37 [45.9%] for ranibizumab and none
for sham).
The mean  SD numbers of injec-
tions administered during 12 months
were 10.2  2.5 and 8.9  3.5 for ranibi-
zumabandsham,respectively.Theinves-
tigators more frequently undertook dose
doubling in the sham arm (45 [91.8%])
than in the ranibizumab arm (70
[68.6%]). Most instances of dose dou-
bling occurred at month 1 (70–78%). A
larger proportion of patients in the sham
arm received rescue laser photocoagula-
tionthanintheranibizumab-treatedarms
(17 [34.7%] and 5 [4.9%], respectively);
among these patients, most received one
to two laser treatments.
Efﬁcacy
The mean average change in BCVA from
baseline to month 1 through 12 (primary
end point) was statistically superior with
ranibizumab (7.8 letters) compared with
sham (0.1 letters) (least squares means
difference 7.9 letters; P  0.0001). At
month 12, mean  SD BCVA improved
by 10.3  9.1 letters from baseline with
ranibizumab and declined by 1.4  14.2
letters with sham (P  0.0001) (Table 1).
Ranibizumab led to a rapid and continu-
ous improvement in mean BCVA, with
superior beneﬁts observed as early as
month 1 (Fig. 1).
The mean BCVA improvement with
ranibizumabtreatmentovertimewaspar-
alleled by improvement in mean CRT
(Fig. 1). The mean change in CRT from
baseline to month 12 was signiﬁcantly
higherintheranibizumabarmthaninthe
sham arm (194.2 vs. 48.4 m, re-
spectively; difference in least squares
means,155m,P0.0001)(Table1).
The impact of therapy on macular edema
(fundus photographs and OCT) is illus-
trated for ranibizumab (0.3–0.6 mg) and
sham in the supplementary data. At
month12,60.8%ofthepatientsreceiving
ranibizumab gained 10 letters of BCVA
from baseline compared with 18.4% in
the sham arm (P  0.0001). A similar
difference was seen in all the other cate-
gories (Table 1).
In terms of the ETDRS severity score,
the observed change from baseline to
month 12 could be analyzed in 50% of
FAS patients. Deterioration within the
categories mild-moderate-severe (0–35,
43–47, and 53) was observed in 3.9%
Table 1—Mean BCVA and CRT at month 12
Ranibizumab pooled Sham
N 102 49
BCVA (ETDRS letters)
Baseline 60.2  9.9 61.1  9.0
Mean average change from baseline to
month 1 through month 12
Average month 1 to month 12 68.0  11.7 61.0  13.9
Average change from baseline 7.8  7.7 0.1  9.8
Comparison vs. sham
Difference in least squares means 7.9 —
95% CI for difference 5.0 to 10.9 —
P value 0.0001 —
Mean change from baseline to month 12
Month 12 70.5  12.1 59.7  17.3
Change from baseline 10.3  9.1 1.4  14.2
Comparison vs. sham
Difference in least squares means 11.9 —
95% CI for difference 8.1 to 15.7 —
P value 0.0001 —
CRT (m)
Baseline 455.4  114.2 448.9  102.8
Month 12 261.2  81.9 400.5  139.2
Comparison vs sham
Change from baseline 194.2  135.1 48.4  153.4
Difference in least squares means 155.0 —
95% CI for difference 195.4 to 114.6 —
P value 0.0001 —
Categorized BCVA outcome, n (%)
Gain of 1 letters* 92 (90.2) 27 (55.1)
Gain of 10 letters* 62 (60.8) 9 (18.4)
Loss of 10 letters* 5 (4.9) 12 (24.5)
Gain of 15 letters† 33 (32.4) 5 (10.2)
Loss of 15 letters† 3 (2.9) 10 (20.4)
DataaremeansSDunlessotherwiseindicated.Ranibizumabdoseandbygroupdata(A,B,andAB)are
presented in supplementary Tables 3 and 4 (available in an online appendix). *P  0.0001; †P  0.0001.
(Test for treatment difference 	ranibizumab vs. sham
, Cochran-Mantel-Haenszel test is of “general associ-
ation.” Stratiﬁed analysis includes baseline visual acuity 	60 or 60 letters
 and baseline CRT 	400 m
or 400 m
.)
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tients, compared with 18% (n  4o f2 2 )
sham patients. Corresponding relevant
improvements were seen in 21.6% (n 
11 of 51) ranibizumab patients, whereas
no such improvement occurred in the
sham patients.
Safety
There were no imbalances in the rates of
ocular and nonocular SAEs or AEs be-
tween the ranibizumab and sham arms
(Table2).Theproportionofpatientswith
ocular SAEs in the study eye was compa-
rable between the treatment arms (ranibi-
zumab: 4 [3.9%]; sham: 1 [2.0%]). Most
of the SAEs were nonocular in origin
(ranibizumab: 14 [13.7%]; sham: 8
[16.3%]). There was one occurrence of
myocardial infarction (nonocular SAE)
with ranibizumab that was suspected to
be related to the study drug. One death
fromurinarybladdercancerwasreported
with ranibizumab, which was not sus-
pected to be related to the study drug or
procedure. Endophthalmitis (n  2o f
102) and myocardial infarction (n  1o f
102) led to study drug discontinuation in
three patients. The most frequently re-
ported ocular AEs (ranibizumab and
sham) were conjunctival hemorrhage, in-
traocular pressure increase, and eye pain
(Table 2). The proportion of patients re-
porting nonocular AEs was comparable
between the ranibizumab and sham arms
(64 [62.7%] and 32 [65.3%], respec-
tively).
The incidence of hypertension and
arterial thromboembolic events, both
possibly due to VEGF inhibition, were
comparable between ranibizumab and
sham arms (hypertension: 9 [8.8%] and 5
[10.2%]; arterial thromboembolic events:
3 [2.9%] and 2 [4.1%], respectively).
There were no clinically signiﬁcant
differences between treatment arms at
baseline for mean serum levels of HbA1C
Table 2—Most frequent SAEs and AEs over 12 months
Ranibizumab pooled Sham
N 102 49
SAEs
Ocular SAEs
Total 4 (3.9) 1 (2.0)
Vitreous hemorrhage* 1 (1.0) 0 (0.0)
Retinal ischemia 1 (1.0) 0 (0.0)
Retinal artery occlusion* 1 (1.0) 0 (0.0)
Endophthalmitis* 2 (2.0) 0 (0.0)
Retinal detachment 0 (0.0) 1 (2.0)
Nonocular SAEs
Total 14 (13.7) 8 (16.3)
Infections and infestations† 2 (2.0) 3 (6.1)
Urinary bladder cancer 1 (2.0) 0 (0.0)
AEs
Ocular AEs
Total 80 (78.4) 28 (57.1)
Conjunctival hemorrhage* 23 (22.5) 7 (14.3)
Eye pain* 18 (17.6) 10 (20.4)‡
Nonocular AEs
Total 64 (62.7) 32 (65.3)
Nasopharyngitis 10 (9.8) 1 (2.0)
Hypertension 7 (6.9) 4 (8.2)
Potentially related to systemic VEGF inhibition
Total 14 (13.7) 6 (12.2)
Arterial thromboembolic events§ 3 (2.9) 2 (4.1)
Hypertension 9 (8.8) 5 (10.2)
Nonocular hemorrhage 2 (2.0) 0 (0.0)
Data are n (%). Additional safety data are presented in supplementary Tables 3, 5, and 6 (available in an
online appendix). *Suspected to be related to study drug/procedure. †Infections and infestations include
gastroenteritis viral, infected epidermal cyst, cellulitis, diabetic gangrene, and gastroenteritis. ‡One event
documented after start of treatment with nonstudy medication (marketed ranibizumab). §Myocardial in-
farction (1 in sham and ranibizumab), retinal artery occlusion (1 in ranibizumab), transient ischemic attack
(1 in ranibizumab), and angina pectoris (1 in sham).
Figure 1—Mean change from baseline to month 12 in (A) BCVA and (B) CRT of the study eye: data for pooled ranibizumab doses (0.3–0.6 and
0.5–1.0 mg) versus sham. Full analysis set, LOCF. (Ranibizumab by-dose data are found in supplementary Fig. 4A and B, available in an online
appendix.)
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Table 7, available in an on online appen-
dix). The urine dipstick protein test was
performed in 60% of the FAS patients.
The deterioration within the categories
(categories 1,2 ,3 , or greater) was
comparable between the ranibizumab
and sham groups (22.9% [n  14 of 61]
and 28.5% [n  8 of 21], respectively),
nonereportedasAEsbytheinvestigators.
Theformationofantibodiestoranibi-
zumabwasreportedinthreepatientspost
baseline. One patient in the sham arm
showed positive immunoreactivity both
at baseline and post baseline.
CONCLUSIONS — Ranibizumab led
to signiﬁcant and continuous improve-
ments in both BCVA and CRT over 12
months compared with sham treatment in
patients with VI due to DME. The safety
proﬁleofranibizumabappearstobesimilar
to that reported for its registered use in
nAMD. Over the 12-month study period,
ranibizumab-treated patients had a mean
average gain in BCVA of 7.8 letters com-
pared with baseline, whereas sham patients
hadameanaveragedecreaseof0.1letter.At
theendofthe12-monthassessmentperiod,
ranibizumab led to a mean gain of 10.3 let-
ters from baseline compared with a decline
of 1.4 letters in the sham patients. The pro-
portion of patients who gained 10 letters
as well as 15 letters was threefold higher
in the ranibizumab arm compared than in
the sham arm.
More patients receiving ranibizumab
hadtheirdoseadjustedbecauseofdisease
improvement (BCVA and/or CRT),
whereas more patients in the sham arm
had their dose adjusted because of lack of
efﬁcacy. Ranibizumab was well tolerated
over 12 months with a safety proﬁle com-
parable to that observed in prior nAMD
studies (20–22). There were no new AEs
reported in patients with DME compared
with patients with nAMD. The incidence
of ocular and nonocular AEs and SAEs
waslow.Thereweretwocasesofendoph-
thalmitis (SAEs) reported in the ranibi-
zumab treatment group (2%). In one
patient, this event resulted in study dis-
continuation, and the event was consid-
ered by the investigator to be related to
the study procedure. In the second pa-
tient, endophthalmitis was considered by
the investigator to be related to the study
medication (because it recurred on re-
challenge).However,thiscaseofendoph-
thalmitis resolved and at study end the
patienthada7-letterBCVAincreasecom-
pared with baseline. The incidence of en-
dophthalmitis (SAE) in the RESOLVE
study (2%) was slightly higher compared
withthatreportedinpriorAMDtrials(0–
1.0%) (23). However, the underlying
sample size and the number of events are
too small to allow for conclusions regard-
ingtheriskofendophthalmitisinpatients
with DME. A recent analysis of safety in
diabetic and nondiabetic patients with
AMD from the AMD trials Anti-VEGF
Antibody for the Treatment of Predomi-
nantly Classic Choroidal Neovasculariza-
tion in AMD (ANCHOR), Minimally
Classic/Occult Trial of the Anti-VEGF
Antibody Ranibizumab in the Treatment
of Neovascular AMD (MARINA), Phase
IIIb, Multicenter, Randomized, Double-
Masked, Sham Injection-Controlled
StudyoftheEfﬁcacyandSafetyofRanibi-
zumab in Subjects with Subfoveal Cho-
roidal Neovasularization with or without
Classic CNV Secondary to Age-Related
Macular Degeneration (PIER), the Safety
Assessment of Intravitreal Lucentis for
AMD (SAILOR), EXCITE, and EXTEND I
(N  3,736) has revealed that the inci-
dences of endophthalmitis were compa-
rable between the diabetic (0.4% [2 of
523]) and nondiabetic patients (0.5% [17
of 3,213]) with AMD, with no indication
of increased risk for the diabetic popula-
tion (24). As in prior nAMD studies eye
pain, conjunctival hemorrhage, and tran-
sient intraocular pressure increase were
the most frequently reported ocular AEs,
and these were suspected to be related to
study procedure (ocular injection).
One of the limitations of this study
was that there was no laser control arm,
butlaserphotocoagulationwaspermitted
as rescue therapy (starting month 3). Ap-
proximately 5% ranibizumab and 35%
sham patients received laser photocoagu-
lation during the study. Furthermore, the
impact of rescue laser treatment on BCVA
outcome was not assessed.
When patients were enrolled, we
were aware that the study required defer-
ral of laser treatment for 3 months or dis-
continuationofpatientswhoneededlaser
photocoagulation within the ﬁrst 3
months of the study. This is at the border
between requiring observation and im-
mediate treatment and we recognize that
it is a judgment that balances the relative
effectiveness and risk of laser treatment.
Examples of the type of eligible clinical
scenarios include DME in the presence of
stable visual acuity for 3 months; DME
associated with leaking microaneurysms,
risk of producing symptomatic perifoveal
scotomata, choroidal neovascularization
or expansion of scarring leading to foveo-
lar atrophy, or borderline reactivation af-
ter prior laser treatment. The relatively
low number of eyes that received photo-
coagulation before or after enrollment
suggests that eyes in which photocoagu-
lation was not considered a good option
were common in this trial. The trial pro-
tocoldidnotincludeanyattempttoguide
investigators as to the exact use of laser
therapy because it was believed that no
satisfactory standard exists for this pur-
pose and that the responsibility had to
remain exclusively with the investigator.
Approximately 20% of eyes had received
prior laser treatment; however, a sub-
group analysis revealed that this treat-
ment had no impact on the BCVA
outcome. Our results should be inter-
pretedwiththesefactorsinmindandmay
not be applicable to more advanced dis-
ease. However, we believe that they are
relevant to patients in the intermediate
stages of the development of DME.
It is proposed that ranibizumab as an
adjunct to laser treatment may be more
effective than either therapy alone; in ad-
dition,thecombinationmayleadtofewer
ranibizumab treatments. The recent Dia-
betic Retinopathy Clinical Research Net-
work (DRCR.net) study showed that
ranibizumab combined with prompt/
deferred laser photocoagulation provided
superior beneﬁts compared with laser
treatment alone in DME (25). However,
results from the earlier READ-2 study
showed that ranibizumab monotherapy
led to superior improvements in BCVA
compared with the combination or laser
photocoagulation alone (14). The
RESTORE study, which assesses the efﬁ-
cacy and safety of 0.5 mg ranibizumab
alone or as an adjunct to laser treatment
compared with laser treatment, will pro-
videfurtherknowledgeoftheefﬁcacyand
safety of ranibizumab either as mono-
therapy or as an adjunct to laser therapy.
The RESOLVE study included a pos-
sibility of dose-doubling that was eventu-
allyundertakeninthemajorityofpatients
receiving ranibizumab. Most patients
(86%) received a dose between 0.5 and
1.0 mg inclusive during the study period.
Dose doubling was included to allow for
best efﬁcacy outcomes, however, the
study was not designed for precise esti-
matesoftheeffectofdosedoubling.Upon
analysis of the actual doses used in each
treatment arm over the study period, the
average dose received was 0.47 mg in
the 0.3–0.6 mg group and 0.76 mg in the
0.5–1.0 mg group. Because these variable
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group within treatment arms, with over-
lapping between treatment arms, the
studyresultsweremainlydiscussedbased
onthepooledranibizumabgroupandare
considered to be representative for treat-
ment with 0.5-mg injections.
Given the nature of diabetes and vari-
ability in patients with DME with regard
to disease progression and vision loss,
there is a need for an individualized treat-
ment regimen. The RESOLVE study al-
lowed for such a dosing regimen, because
retreatment (after three monthly injec-
tions) was based on predeﬁned visual
acuity/CRT and safety criteria; this con-
ceptpartlymimicsclinicalpractice.How-
ever, unlike clinical practice, the visual
acuity/CRT criteria adopted in the study
were stringent to increase the likelihood
of patient beneﬁt.
Results from the RESOLVE study in-
dicate that DME responds well to treat-
mentwithintravitrealranibizumabover1
year. In light of the sustained improve-
ments in BCVA and CRT over the 12-
month study period combined with a
good safety proﬁle, ranibizumab appears to
be a promising pharmacological agent for
the management of visual impairment due
toDME.Theseresultsprovideastrongbasis
for continuing development of ranibi-
zumab in phase III trials in DME, and this
study is a stepping stone toward increasing
the treatment options for these patients.
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